PPH:NSD-VanEck Vectors Pharmaceutical ETF

ETF | Others | NASDAQ Global Market

Last Closing

USD 57.05

Change

+0.31 (+0.55)%

Market Cap

USD 0.25B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors? US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Pharmaceutical Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Inception Date: 20/12/2011

Primary Benchmark: MVIS US Listed Pharmaceutical 25 NR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.41%

Management Expense Ratio: 0.36 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-10-16 )

Largest Industry Peers for Others

Symbol Name Mer Price(Change) Market Cap
QQQM Invesco NASDAQ 100 ETF 0.00 %

+1.72 (+1.01%)

USD 22.00B
ACWI iShares MSCI ACWI ETF 0.00 %

+1.06 (+1.01%)

USD 19.51B
IBIT iShares Bitcoin Trust 0.00 %

+1.26 (+3.44%)

USD 17.74B
CGABL The Carlyle Group Inc. 4.625% .. 0.00 %

+0.27 (+1.47%)

USD 16.14B
JEPQ JPMorgan Nasdaq Equity Premium.. 0.00 %

+0.47 (+0.92%)

USD 11.73B
TBIL Rbb Fund Inc - Us Treasury 3 M.. 0.00 %

N/A

USD 3.07B
IBTE iShares iBonds Dec 2024 Term T.. 0.00 %

N/A

USD 2.86B
IBTF iShares iBonds Dec 2025 Term T.. 0.00 %

N/A

USD 2.25B
USCL iShares Climate Conscious & Tr.. 0.00 %

+0.46 (+0.79%)

USD 2.01B
RILYK B. Riley Financial Inc. 5.50% .. 0.00 %

+0.07 (+0.37%)

USD 1.95B

ETFs Containing PPH

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.12% 19% F 45% F
Dividend Return 1.24% 42% F 31% F
Total Return 5.37% 17% F 44% F
Trailing 12 Months  
Capital Gain -9.29% 11% F 46% F
Dividend Return 1.41% 34% F 29% F
Total Return -7.88% 11% F 46% F
Trailing 5 Years  
Capital Gain -2.04% 24% F 42% F
Dividend Return 9.76% 44% F 37% F
Total Return 7.71% 20% F 42% F
Average Annual (5 Year Horizon)  
Capital Gain -3.32% 7% C- 31% F
Dividend Return -1.42% 9% A- 32% F
Total Return 1.91% 64% D 52% F
Risk Return Profile  
Volatility (Standard Deviation) 10.27% 52% F 87% B+
Risk Adjusted Return -13.81% 11% F 29% F
Market Capitalization 0.25B 60% D- 41% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.